Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
5Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Immix Biopharma, Inc. (IMMX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
4Distinct source URLs
11High confidence
0.796Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Immix Biopharma, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CITIZENS-JMP-SECURITIES-LLC
CITIZENS-JMP-SECURITIES-LLC
92%
On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 ("Amendment No. 1") to that certain At The Market Offeri…
U-S-MEDICAL-RESEARCH-FOUNDATION
U-S-MEDICAL-RESEARCH-FOUNDATION
92%
In August 2024, the Company entered into a Patent License Agreement with a U.S. medical research foundation pursuant to which the Company was granted certain exclusive and nonexclusive licenses and s…
BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD
BIRAD-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD
90%
Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT
HADASIT-MEDICAL-RESEARCH-SERVICES-DEVELOPMENT-LT
90%
Pursuant to the Agreement, Nexcella paid the Licensors an upfront fee of $1,500,000 in December 2022.
NEXCELLA-INC
NEXCELLA-INC
90%
Research and License Agreement entered into on November 27, 2022 by and between Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.), Hadasit Medical Research Services & Development, Ltd. and…
THIRD-PARTY-CONTRACT-MANUFACTURERS
THIRD-PARTY-CONTRACT-MANUFACTURERS
80%
We do not have any long-term manufacturing and supply agreements with our third-party contract manufacturers, but we enter into specific contracts on an as needed basis for individual batch productio…
THIRD-PARTY-CONTRACT-ORGANIZATIONS
THIRD-PARTY-CONTRACT-ORGANIZATIONS
80%
The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (…
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
70%
The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including... contract manufa…
Immix Biopharma, Inc. Customers
Ticker
Name
Confidence
Evidence
CITIZENS-JMP-SECURITIES-LLC
CITIZENS-JMP-SECURITIES-LLC
62%
hman will be entitled only to his base salary through the date of termination, valid expense reimbursements and unused vacation pay. If terminated by the Company without “cause” or by Dr. Rachman wit…
DEVELOPMENT-COMPANY-LTD
DEVELOPMENT-COMPANY-LTD
62%
hman will be entitled only to his base salary through the date of termination, valid expense reimbursements and unused vacation pay. If terminated by the Company without “cause” or by Dr. Rachman wit…
DEVELOPMENT-LTD
DEVELOPMENT-LTD
62%
hman will be entitled only to his base salary through the date of termination, valid expense reimbursements and unused vacation pay. If terminated by the Company without “cause” or by Dr. Rachman wit…
IMMIX-BIOPHARMA-AUSTRALIA-PTY-LTD
IMMIX-BIOPHARMA-AUSTRALIA-PTY-LTD
62%
nducted by us or others; ● our ability to obtain and maintain intellectual property protection for our current and future product candidates; ● our ability to protect our intellectual property rights…
OVERVIEW-IMMIX-BIOPHARMA-INC
OVERVIEW-IMMIX-BIOPHARMA-INC
62%
hman will be entitled only to his base salary through the date of termination, valid expense reimbursements and unused vacation pay. If terminated by the Company without “cause” or by Dr. Rachman wit…
Immix Biopharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMMX-DEBT
Debt stack $1.0M
90%
Market cache reports total debt of $1.0M.
IMMX-DEBT-10240
Warrants outstanding: 31500
90%
xbrl warrant detail from xbrl 2026-03-31.
IMMX-DEBT-10241
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Immix Biopharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Immix Biopharma, Inc..
Immix Biopharma, Inc. Ownership
Holder
Name
Confidence
Evidence
IMMX-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 77 tracked holders.
Immix Biopharma, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
